OnPoint Vision, Inc. Files for IDE Application to Begin Pivotal IOPCL Clinical Trial

PRESS RELEASE ALISO VIEJO, Calif., May 12, 2023, OnPoint Vision Inc, a privately held ophthalmic medical device company, announced the filing of their Investigational Device Exemption (IDE) application to begin their pivotal clinical trial of the Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) aka “CADY” study for secondary implantation in the capsular bag with a … Read more

OnPoint’s AccuraSee IOPCL Presentation at Max Symposium

At this year’s ASCRS, John Hovanesian, MD will be presenting OnPoint’s AccuraSee IOPCL during the X-Rounds Refractive Cataract Surgery to the Max Symposium. This fast-paced session will feature the latest and greatest in refractive cataract surgery. The title of the “debate” is: The Best New Technologies on the Horizon”. We are honored and humbled to … Read more

AccuraSee IOPCL Scored High at AECOS

Kevin Cady, OnPoint Vision president, was honored to present at the American-European Congress of Ophthalmic Surgeons (AECOS), hosted at the beautiful St. Regis Resort, Deer Valley, Utah. The AccuraSee IOPCL (AKA: CadyLens) scored high among the physician attendees. Cady was humbled by the overall enthusiastic response and congratulatory messages received from many of the Key … Read more

Healio Ocular Surgery News: The IOL that Forgives

Blog article by John A. Hovanesian, MD, FACSApril 18, 2022 Dr. Hovanesian reported on his experience implanting the first AccuraSee™ intraocular pseudophakic contact lens to improve near vision in patients with macular degeneration. “This is a fascinating invention from Kevin J. Cady, an eye care industry veteran who devised a small implant that rests on … Read more

Harvard Eye Associates Surgeons Implant the First U.S. AccuraSee™ IOPCL to Treat Macular Degeneration

Laguna Hills, Ca.— Harvard Eye Associates reported that its surgeons have implanted the first worldwide AccuraSee™ Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. Macular degeneration, the country’s leading cause of legal blindness in people over age 65, is a disease caused by aging of the delicate cells in … Read more

President & CEO

Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies.  Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.

Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the  invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.